Financial overview
Prostatype Genomics financial report data and keyfigures. History for income statement, balance sheet and cash flow.
Description
Prostatype Genomics conducts research and development of medical devices and drugs. Prostatype Genomics AB is the result of over ten years of research work in the genomics of prostate cancer. The company was founded in 2007 as a spin-off from Cancer Center Karolinska. The purpose of the spin-off was to transfer the research results to clinical reality. The result of this was the development of the today CE-marked and market-ready product Prostatype Test System. The unique system of the prostate type identifies the genetic fingerprint of prostate cancer by measuring information from the genes of the cancer stem cells in the tissue sample already obtained in connection with the patient's diagnosis. By combining the genetic fingerprint with other information from the diagnosis, a so-called P-score is calculated.